ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2014

Abstract Number: 3014

Does the Order or Amount of Risk-Benefit Information Presented Influence patients’ Perceived Value of a Proposed New Medication?

Liana Fraenkel1, Richard Street2, Harjinder Chowdhary3, Sarah Swift3 and Ellen Peters4, 1Rheumatology, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT, 2Texas A&M University, College Station, TX, 3Yale University, New Haven, CT, 4Ohio State University, Columbus, OH

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2014

Keywords: Racial Disparities and Risk Communication

Session Information

Title: Innovations in Rheumatologic Care

Session Type: Abstract Submissions (ARHP)

Background/Purpose: The order and amount of information has been shown to influence risk perceptions related to hazards. In this study we sought to examine whether order and amount of risk and benefit information influences patients’ perceived value of a proposed new medication.

Methods: We created 5 videos of a physician describing a new medication. The videos were identical except for the order and number of side effects (SEs) and benefits presented (see Table). Subjects with a systemic inflammatory rheumatic disease were randomly assigned to view one of the videos. Perceived medication value (PMV) was assessed by having subjects choose: the risks outweigh the benefits, the risks and benefits are equally balanced or the benefits outweigh the risks. We subsequently examined whether differences in the order and amount of information was associated with subjects’ PMV. This outcome was chosen because one’s overall impression more strongly predicts behavior than recall of verbatim information. We also examined the association of demographic characteristics (age, minority status, and difficulty paying for medications), attitudes towards illness and treatment (factor analysis of illness perceptions, patient activation and trust resulting in 4 factors: worry about illness, perceived treatment efficacy, impact of illness, patient activation), and current medications on PMV using bivariate analyses. Variables found to be significant (p<0.05) were included in a multinomial logistic regression model. Because of the known influence of numeracy on risk perception, all analyses were stratified by high versus low subjective numeracy (dichotomized at the median).

Results: 389 subjects participated: mean (SD) age= 55 (14), 75% female, 40% minority (African American and/or Hispanic). In bivariate analyses, the order and number of SEs and benefits, current use of prednisone, and minority status were associated with PMV in subjects with high numeracy (n=242). Presenting SEs first or between benefits were both associated with more negative PMV compared to the reference video (3 benefits followed by 6 SEs) (See Table). Among subjects with low numeracy (n=142), the order and number of risk and benefits presented were not associated with PMV. In bivariate analyses, use of a biologic, difficulty paying for medications, perceived treatment efficacy, patient activation, and minority status, were associated with PMV in subjects with low numeracy. Except for current use of a biologic, all remained significant in the multivariate model (see Table).

Conclusion: Order and amount of information matter, but only in patients with high subjective numeracy. Minority patients have a much more negative PMV compared to Caucasian, non-Hispanic patients, regardless of their level of numeracy.

Table: Multinomial logistic regression model examining association of risk-benefit presentation and patients characteristics on perceived medication value.

Variable

Perceived   Medication Value (Ref= Risks outweigh Benefits)

Adjusted   Odd Ratio (95% CI)

High   Numeracy

 

 

Video (Ref= 3 benefits   → 6 SEs)

 

 

6 benefits → 6 SEs

Balanced

1.87   (0.59 – 5.98)

 

Benefits outweigh   Risks

0.45   (0.14 – 1.48)

6 benefits → 3 SEs

Balanced

0.79   (0.24 –  2.64)

 

Benefits outweigh   Risks

0.60   (0.19 – 1.83)

6 SEs → 3 benefits

Balanced

0.47   (0.16 – 1.40)

 

Benefits outweigh   Risks

0.20 (0.07 – 0.58)

3 benefits → 6 SEs → 3   benefits

Balanced

0.54   (0.18 – 1.66)

 

Benefits outweigh   Risks

0.26   (0.09 – 0.78)

Currently on   prednisone

Balanced

0.75 (0.34 – 1.67)

 

Benefits outweigh   Risks

1.77 (0.82 – 3.80)

Minority vs Caucasian

Balanced

0.95   (0.48 – 1.89)

 

Benefits outweigh   Risks

0.25 (0.11 – 0.58)

 

 

 

Low   Numeracy

 

 

Perceived treatment   efficacy

Balanced

1.46   (0.90 – 2.37)

 

Benefits outweigh   Risks

2.22 (1.28 – 3.83)

Patient activation

Balanced

1.75 (1.09 – 2.81)

 

Benefits outweigh   Risks

1.05   (0.62 – 1.78)

Currently on a   biologic

Balanced

1.13   (0.35 – 3.66)

 

Benefits outweigh   Risks

2.64   (0.87 – 8.04)

Difficulty paying for   medications

Balanced

0.17 (0.07 – 0.44)

 

Benefits outweigh   Risks

0.73   (0.27 – 2.00)

Minority vs Caucasian

Balanced

0.23 (0.09 – 0.62)

 

Benefits outweigh   Risks

0.22 (0.08 – 0.63)


Disclosure:

L. Fraenkel,
None;

R. Street,
None;

H. Chowdhary,
None;

S. Swift,
None;

E. Peters,
None.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/does-the-order-or-amount-of-risk-benefit-information-presented-influence-patients-perceived-value-of-a-proposed-new-medication/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology